10x Genomics Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, 10x Genomics stock has a consensus rating of "Buy" and an average price target of $25.77. The average 1-year stock price forecast is 10.64% lower than the current stock price, while the lowest is $20 (-30.65%) and the highest is $32 (+10.96%).

Price Target: $25.77 (-10.64%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$20	$25.77	$25	$32
Change	-30.65%	-10.64%	-13.31%	+10.96%

Analyst Ratings

The average analyst rating for 10x Genomics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	4	4	5	5	5	5
Buy	1	1	1	1	1	1
Hold	12	12	10	10	10	10
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	17	17	16	16	16	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kyle Mikson CFA Canaccord Genuity	Canaccord Genuity	Buy Maintains $32	Buy	Maintains	$32	+10.96%	Jun 5, 2026
Michael Ryskin Bank of America Securities	Bank of America Securities	Hold Maintains n/a	Hold	Maintains	n/a	n/a	May 14, 2026
Kallum Titchmarsh Morgan Stanley	Morgan Stanley	Hold Maintains $20 → $22	Hold	Maintains	$20 → $22	-23.72%	May 12, 2026
Casey Woodring J.P. Morgan	J.P. Morgan	Hold Maintains $17 → $20	Hold	Maintains	$17 → $20	-30.65%	May 12, 2026
Matt Larew William Blair	William Blair	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

613.48M

from 642.82M

-4.56%

from 642.82M

Revenue Next Year

667.70M

from 613.48M

8.84%

from 613.48M

EPS This Year

n/a

from 0.12

-100.00%

from 0.12

EPS Next Year

0.20

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	490.49M	516.41M	618.73M	610.79M	642.82M	613.48M
Revenue Growth	64.13%	5.28%	19.81%	-1.28%	5.24%	-4.56%
Gross Profit	416.40M	396.32M	409.31M	414.48M	444.38M	413.62M
Gross Margin	84.89%	76.75%	66.15%	67.86%	69.13%	67.42%
Operating Income	-52.91M	-163.74M	-199.75M	-193.46M	-100.29M	-116.33M
Net Income	-58.22M	-166.00M	-255.10M	-182.63M	-43.54M	-104.38M
EPS	-	-	-	-	0.12	-
EPS Growth	-	-	-	-	-	-100.00%
Free Cash Flow	-67.02M	-92.66M	27.63M	59.20M	148.39M	16.00M
No. Analysts	-	-	-	-	-	15

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	618.4M
Avg	613.5M
Low	605.5M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-3.8%
Avg	-4.6%
Low	-5.8%

EPS Forecast

EPS	2026	2027	2028
High	0.06
Avg	-
Low	-0.06

EPS Growth

EPS Growth	2026	2027	2028
High	-51.3%
Avg	-100.0%
Low	-